Jim T Vehmeijer1, Tom F Brouwer1, Jacqueline Limpens2, Reinoud E Knops1, Berto J Bouma1, Barbara J M Mulder3, Joris R de Groot4. 1. Department of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, PO Box 22700, 1100 DE, Amsterdam, The Netherlands. 2. Medical Library, Academic Medical Center, Amsterdam, The Netherlands. 3. Department of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, PO Box 22700, 1100 DE, Amsterdam, The Netherlands Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands. 4. Department of Clinical and Experimental Cardiology, Heart Center, Academic Medical Center, PO Box 22700, 1100 DE, Amsterdam, The Netherlands j.r.degroot@amc.uva.nl.
Abstract
AIMS: Sudden cardiac death is a major cause of mortality in adult congenital heart disease (ACHD) patients. The indications for implantable cardioverter-defibrillator (ICD) implantation in ACHD patients are still not well established. We aim to systematically review the literature on indications and outcome of ICD implantation in ACHD patients. METHODS AND RESULTS: We performed a comprehensive search in EMBASE, MEDLINE, and Google Scholar to identify all studies on ICD implantation in ACHD patients. We used random effects models to calculate proportions and 95% confidence intervals. Of 1356 articles, 24 studies with 2162 patients were included, with a mean follow-up of 3.6 ± 0.9 years. Half of patients had tetralogy of Fallot. Mean age at implantation was 36.5 ± 5.5 years old and 66% was male. Implantable cardioverter-defibrillators were implanted for primary prevention in 53% (43.5-62.7). Overall, 24% (18.6-31.3) of patients received one or more appropriate ICD interventions (anti-tachycardia pacing or shocks) during 3.7 ± 0.9 years: 22% (16.9-28.8) of patients with primary prevention in 3.3 ± 0.3 years and 35% (26.6-45.2) of patients with secondary prevention in 4.3 ± 1.2 years. Inappropriate shocks occurred in 25% (20.1-31.0) in 3.7 ± 0.8 years and other, particularly lead-related complications in 26% (18.9-33.6) of patients in 3.8 ± 0.8 years. All-cause mortality was 10% during 3.7 ± 0.9 years. CONCLUSIONS: In ACHD, remarkably high rates of appropriate ICD therapy were reported, both in primary and secondary prevention. Because of the young age and lower death rates, the cumulative beneficial effects are likely greater in ACHD patients than in acquired heart disease patients. However, considering the high rates of inappropriate shocks and complications, case-by-case weighing of costs and benefits, remains essential. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Sudden cardiac death is a major cause of mortality in adult congenital heart disease (ACHD) patients. The indications for implantable cardioverter-defibrillator (ICD) implantation in ACHD patients are still not well established. We aim to systematically review the literature on indications and outcome of ICD implantation in ACHD patients. METHODS AND RESULTS: We performed a comprehensive search in EMBASE, MEDLINE, and Google Scholar to identify all studies on ICD implantation in ACHD patients. We used random effects models to calculate proportions and 95% confidence intervals. Of 1356 articles, 24 studies with 2162 patients were included, with a mean follow-up of 3.6 ± 0.9 years. Half of patients had tetralogy of Fallot. Mean age at implantation was 36.5 ± 5.5 years old and 66% was male. Implantable cardioverter-defibrillators were implanted for primary prevention in 53% (43.5-62.7). Overall, 24% (18.6-31.3) of patients received one or more appropriate ICD interventions (anti-tachycardia pacing or shocks) during 3.7 ± 0.9 years: 22% (16.9-28.8) of patients with primary prevention in 3.3 ± 0.3 years and 35% (26.6-45.2) of patients with secondary prevention in 4.3 ± 1.2 years. Inappropriate shocks occurred in 25% (20.1-31.0) in 3.7 ± 0.8 years and other, particularly lead-related complications in 26% (18.9-33.6) of patients in 3.8 ± 0.8 years. All-cause mortality was 10% during 3.7 ± 0.9 years. CONCLUSIONS: In ACHD, remarkably high rates of appropriate ICD therapy were reported, both in primary and secondary prevention. Because of the young age and lower death rates, the cumulative beneficial effects are likely greater in ACHD patients than in acquired heart diseasepatients. However, considering the high rates of inappropriate shocks and complications, case-by-case weighing of costs and benefits, remains essential. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews Journal: N Engl J Med Date: 2002-03-19 Impact factor: 91.245
Authors: Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip Journal: N Engl J Med Date: 2005-01-20 Impact factor: 91.245
Authors: Zeliha Koyak; Louise Harris; Joris R de Groot; Candice K Silversides; Erwin N Oechslin; Berto J Bouma; Werner Budts; Aeilko H Zwinderman; Isabelle C Van Gelder; Barbara J M Mulder Journal: Circulation Date: 2012-09-18 Impact factor: 29.690
Authors: Kevin A Michael; Gruschen R Veldtman; John R Paisey; Arthur M Yue; Stephen Robinson; Stuart Allen; Nadia S Sunni; Chris Kiesewetter; Tony Salmon; Paul R Roberts; John M Morgan Journal: Europace Date: 2007-03-23 Impact factor: 5.214
Authors: Louise R A Olde Nordkamp; Lara Dabiri Abkenari; Lucas V A Boersma; Alexander H Maass; Joris R de Groot; Antonie J H H M van Oostrom; Dominic A M J Theuns; Luc J L M Jordaens; Arthur A M Wilde; Reinoud E Knops Journal: J Am Coll Cardiol Date: 2012-10-10 Impact factor: 24.094
Authors: Thomas Korte; Harald Köditz; Michael Niehaus; Thomas Paul; Jürgen Tebbenjohanns Journal: Pacing Clin Electrophysiol Date: 2004-07 Impact factor: 1.976
Authors: Bo Kyung Jin; Ji Seok Bang; Eun Young Choi; Gi Beom Kim; Bo Sang Kwon; Eun Jung Bae; Chung Il Noh; Jung Yun Choi; Woong Han Kim Journal: Korean J Pediatr Date: 2013-03-18
Authors: Michael Huntgeburth; Christopher Hohmann; Harald Kaemmerer; Christof Kolb; Peter Ewert; Sebastian Freilinger; Nicole Nagdyman; Rhoia Neidenbach; Lars Pieper; Felix Pieringer; Carsten Lennerz Journal: Cardiovasc Diagn Ther Date: 2021-12
Authors: J T Vehmeijer; Z Koyak; A H Zwinderman; L Harris; R Peinado; E N Oechslin; C K Silversides; B J Bouma; W Budts; I C van Gelder; J M Oliver; B J M Mulder; J R de Groot Journal: Neth Heart J Date: 2019-10 Impact factor: 2.380